Generate Biomedicines

Generate Biomedicines is a Somerville, Massachusetts therapeutics company pioneering Generative Biology, a machine-learning-driven approach to de novo protein design across antibodies, peptides, enzymes, and gene therapies. Founded out of Flagship Pioneering and chaired by Noubar Afeyan, the company trains generative models on the full compendium of natural protein structures and sequences plus proprietary wet-lab data to design novel protein therapeutics computationally rather than by trial-and-error discovery. Its open-source flagship is Chroma, a programmable diffusion-based generative model for joint protein structure and sequence design published in Nature 2023 ("Illuminating protein space with a programmable generative model", doi:10.1038/s41586-023-06728-8) and released on GitHub under Apache 2.0 with pretrained weights available under a custom Chroma Parameters License (free for academic and nonprofit use). Chroma uses equivariant graph neural networks, diffusion modeling, and conditional random fields to sample all-atom protein structures with sub-quadratic complexity, supporting conditional generation via composable Conditioner modules for symmetry, substructure, shape, and secondary-structure constraints. The internal Generate Platform iterates on a "generate, build, measure, learn" loop that pairs in-silico design with high-throughput protein synthesis and characterization; the company reports having generated, built, and tested more than 42,000 proteins. Generate Biomedicines has platform collaborations with Amgen (six programs, January 2022) and Novartis (multiple programs, September 2024) and a CAR T collaboration with Roswell Park. Its clinical pipeline is led by GB-0895, a long-acting anti-TSLP antibody for severe asthma now in Phase 3 (SOLAIRIA study) with a parallel Phase 1 in COPD, plus preclinical programs GB-4362 (anti-free-MMAE for ADC oncology safety) and GB-5267 (MUC16 armored CAR T for ovarian cancer). The company priced its initial public offering in February 2026. Revenue derives from drug development, partner collaborations, and (for Chroma) commercial weights licensing; there is no public developer REST/HTTPS API or SDK for the Generate Platform itself — Chroma is consumed as a Python library installed via pip with model weights downloaded from chroma-weights.generatebiomedicines.com after registering for an API key.

Kin Score

This is the API Evangelist rating — a single, repeatable read computed from the artifacts on this page. Green fill is points earned; the red track is points possible, so every bar shows earned-versus-possible at a glance.

How we profile Generate Biomedicines

Each block below is one kind of artifact we hold for Generate Biomedicines. For each we say what it is and why it earns a place in the profile, then list every one we've indexed — capped at two rows, scroll within the panel for the rest.

Security Posture 1

Authentication, domain security, vulnerability disclosure, and trust-center signals — the evidence that a provider takes security seriously enough to document it. We profile it because you can't govern what you can't see.

Authentication, domain security, vulnerability disclosure, and trust-center signals.

Generate Biomedicines Domain Security

TLSv1.3 · DMARC

SECURITY

Resources

Every other property we hold for Generate Biomedicines — documentation, portals, status pages, policies, and corporate surface — grouped by the job it does, following the integrator's arc from getting started to running in production.

← All providers · Data indexed from github.com/api-evangelist/generate-biomedicines · machine-readable index on apis.io